Pharmacy study of natural health product adverse reactions (SONAR): A cross-sectional study using active surveillance in community pharmacies to detect adverse events associated with natural health products and assess causality

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Necyk, Candace ^a   Tsuyuki, Ross T ^a   Boon, Heather ^b   Foster, Brian C ^c   LeGatt, Don ^d   Cembrowski, George ^d   Murty, Mano ^e   Barnes, Joanne ^f   Charrois, Theresa L ^g   Arnason, John T ^c   Ware, Mark A ^h   Rosychuk, Rhonda J ^a   Vohra, Sunita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e HEALTH CANADA   (Canada)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g CURTIN UNIVERSITY   (Australia)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETAHISTINE; BISOPROLOL; CAFFEINE; CALCIUM; CALCIUM CARBONATE; CLOPIDOGREL; CYCLOBENZAPRINE; ESCITALOPRAM; ETHINYLESTRADIOL; EZETIMIBE; GABAPENTIN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; KETOROLAC; LEVOTHYROXINE; LINSEED OIL; MAGNESIUM; MULTIVITAMIN; NAPROXEN; NATURAL HEALTH PRODUCT; NATURAL PRODUCT; OMEGA 3 FATTY ACID; PARACETAMOL; PRESCRIPTION DRUG; RAMIPRIL; ROSUVASTATIN; SERTRALINE; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; BIOLOGICAL PRODUCT;

ADULT; AGED; ARTICLE; CANADA; CHILD; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHARMACIST; PHARMACY; PILOT STUDY; PRESCRIPTION; TELEPHONE INTERVIEW; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BRITISH COLUMBIA; DEMOGRAPHY; DRUG INTERACTION; MIDDLE AGED; ONTARIO; PRESCHOOL CHILD; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL PRODUCTS; BRITISH COLUMBIA; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; ONTARIO; PHARMACIES; PHARMACISTS; PRESCRIPTION DRUGS; RESIDENCE CHARACTERISTICS; SURVEYS AND QUESTIONNAIRES;

EID: 84897532653     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003431     Document Type: Article

References (49)

1. Natural Health Products Directorate - Health Canada. Natural Health Product Tracking Survey - 2010 Final Report. Ipsos-Reid. March 13 2011. http://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2011/135-09/ report.pdf (accessed 30 Mar 2012).
2. Vicki Wood. OTC Market Report 2012: introduction. Canadian Healthcare Network. 2012. http://www.canadianhealthcarenetwork.ca/pharmacists/clinical/otc/ otc-market-report-2012-introduction-16126 (accessed 11 Nov 2012).
3. Walji R, Boon H, Barnes J, et al. Reporting natural health product related adverse drug reactions: is it the pharmacist's responsibility? Int J Pharm Pract 2011;19:383-91.
4. Barnes PM, Stussman BJ, Bloom B. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report 2009;1-14.
5. Xue CC, Zhang AL, Lin V, et al. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med 2007;13:643-50. (Pubitemid 47357086)
6. Corazza M, Borghi A, Lauriola MM, et al. Use of topical herbal remedies and cosmetics: a questionnaire-based investigation in dermatology out-patients. J Eur Acad Dermatol Venereol 2009;23:1298-303.
7. Natural Health Products Regulations. Food and Drugs Act. Health Canada. 2003. http://gazette.gc.ca/archives/p2/2003/2003-06-18/html/sor-dors196-eng.html (accessed 11 Nov 2012).
8. Felix S. OTC Market Report 2009: more often, self-care means going natural. Canadian Healthcare Network. 1 April 2009. http://www. canadianhealthcarenetwork.ca/pharmacists/clinical/otc/otc-market-report-2009- more-often-self-care-means-going-natural-1055 (accessed 11 Nov 2012).
9. Charrois TL, Hill RL, Vu D, et al. Community identification of natural health product drug interactions. Ann Pharmacother 2007;41:1124-9. (Pubitemid 47122548)
10. Wysong P. 38% of doctors now suggest natural health products: survey. Canadian Healthcare Network. May 18, 2011. http://www.canadianhealthcarenetwork. ca/pharmacists/clinical/health-index-therapeutics/alternative-medicine/ 38-of-doctors-now-suggest-natural-health-products-survey-11135 (accessed 11 Nov 2012).
11. Shaw D, Ladds G, Duez P, et al. Pharmacovigilance of herbal medicine. J Ethnopharmacol 2012;140:513-18.
12. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003;26:829-51. (Pubitemid 37188247)
13. Walji R, Boon H, Barnes J, et al. Adverse event reporting for herbal medicines: a result of market forces. Healthc Policy 2009;4:77-90.
14. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol 2013;69:295-307.
15. Chitturi S, Farrell G. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2008;23:366-73. (Pubitemid 351342073)
16. Roy-Byrne PP, Bystritsky A, Russo J, et al. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics 2005;46:117-22. (Pubitemid 41071496)
17. Quandt SA, Chen H, Grzywacz JG, et al. Use of complementary and alternative medicine by persons with arthritis: results of the National Health Interview Survey. Arthritis Rheum 2005;53:748-55. (Pubitemid 41463841)
18. Wood MJ, Stewart RL, Merry H, et al. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003;145:806-12. (Pubitemid 36570950)
19. Vohra S, Cvijovic K, Boon H, et al. Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PLoS ONE 2012;7:e45196.
20. Morgan TK, Williamson M, Pirotta M, et al. A national census of medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012;196:50-3.
21. Tessa KM, Margaret W, Jared AB, et al. Medication safety issues in older Australians. Results from a national medicines census. Joint ASCEPT-APSA conference 2012, Sydney Convention and Exhibition Centre, Sydney, Australia, December 2-5, 2012. Australian Society of Clinical and Experimental Pharmacology and Therapeutics - Australian Pharmaceutical Science Association.
22. Pal S, Dodoo A, Mantel A, et al. The World Medicines Situation 2011: pharmacovigilance and safety of medicines. World Health Organization 2011. http://apps.who.int/medicinedocs/documents/s18771en/s18771en.pdf (accessed 11 Nov 2012).
23. Wiktorowicz ME, Lexchin J, Moscou K, et al. Keeping an eye on prescription drugs, keeping Canadians safe: a commissioned discussion paper. Health Council of Canada 2010 http://publications.gc.ca/collections/collection- 2011/ccs-hcc/H174-21-2010-eng.pdf (accessed 30 Mar 2012).
24. World Health Organization (WHO). Note for guidance on clinical safety data management: definitions and standards for expedited reporting. Geneva: Author; 1995. CPMP/ICH.377/95.
25. van Grootheest K, Olsson S, Couper M, et al. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004;13:457-64.
26. Raynor DK, Dickinson R, Knapp P, et al. Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med 2011;9:94.
27. Ulbricht CE, Basch EM. eds. Natural standard herb & supplement reference: evidence-based clinical reviews. St Louis, MO: Elsevier Mosby, 2005.
28. Cvijovic K, Boon H, Brulotte J, et al. A tool for rapid identification of potential herbal medicine-drug interactions. Can Pharm J 2009;142:224-7.
29. WHO adverse drug event causality assessment criteria, Uppsala drug monitoring centre. http://www.who-umc.org/DynPage.aspx?id=22682. (accessed 2012 Apr 6).
30. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
31. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. (Pubitemid 46625492)
32. Stata data analysis and statistical software version 12.0. StataCorp LP. Texas, USA.
33. Cvijovic K, Boon H, Jaeger W, et al. Pharmacists' participation in research: a case of trying to find the time. Int J Pharm Pract 2010;18:377-83.
34. Marketed Health Products Directorate. Memo. 30 May 2012.
35. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-96.
36. Macedo AF, Alves C, Craveiro N, et al. Multiple drug exposure as a risk factor for the seriousness of adverse drug reactions. J Nurs Manag 2011;19:395-9.
37. Canadian Pharmacists Association. Expanding the role of pharmacists. http://pharmacists-ca.inf.ca/content/consumer-patient/resource-centre/working/ pdf/Expanding-the-Role-of-Pharmacists-Mar07.pdf (accessed 30 Oct 2012).
38. Jean D, Cyr C. Use of complementary and alternative medicine in a general pediatric clinic. Pediatrics 2007;120:e138-41. (Pubitemid 47036227)
39. Goldman RD, Vohra S, Rogovik AL. Potential vitamin-drug interactions in children at a paediatric emergency department. Paediatr Drugs 2009;11:251-7.
40. Pharmanet. Ministry of Health. Government of British Columbia. http://www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html (accessed 30 Oct 2012).
41. Menniti-Ippolito G, Raschetti R, Da Cas R, et al. Active monitoring of adverse drug reactions in children. Lancet 2000;355:1613-14. (Pubitemid 30240508)
42. Talabi M, Jeschke E, Bockelbrink A, et al. Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine. BMC Public Health 2009;9:274.
43. Salvo F, Miroddi M, Alibrandi A, et al. Attitudes and opinion about adverse drug events of women living in a city of south Italy. Pharmacology 2013;91:173-7.
44. MacDonald L, Foster BC, Akhtar H. Food and therapeutic product interactions - a therapeutic perspective. J Pharm Pharm Sci 2009;12:367-77.
45. Agbonon A, Eklu-Gdegbeku K, Kodjo, et al. In vitro inhibitory effect of West African medicinal and food plants on human cytochrome P450 3A subfamily. J Ethnopharmacol 2010;128:390-4.
46. Cvijovic K, Boon H, Jaeger W, et al. SONAR group. Polypharmacy, multiple natural health products and hepatotoxicity. CMAJ 2011;183:E1085-9.
47. Sheehan NL, van Heeswijk RP, Foster BC, et al. The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients. Molecules 2012;17:688-702.
48. Foster BC, Arnason JT, Saleem A, et al. Comparative study of hops-containing products on human cytochrome P450-mediated metabolism. J Agric Food Chem 2011;59:5159-63.
49. Necyk C, Barnes J, Tsuyuki RT, et al. How well do pharmacists know their patients? A case report highlighting natural health product disclosure. Can Pharm J 2013;146:202-9.